Immune Checkpoint Inhibitors Market Global Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast 2019 to 2026

Immune Checkpoint Inhibitors Market Global Trends, Market Share, Industry Size,
Growth, Opportunities, and Market Forecast 2019 to 2026
Immune checkpoint inhibitors market to value over USD 26 Billion by 2029 end and
register a CAGR of over 13.6% from 2019 to 2029.
Immune checkpoint inhibitor is an eminent sphere of Immuno-oncology therapies. It
is employed in the treatment of cancer by activating and strengthening the body’s
immune system to fight the disease. The therapies and inhibitors target the immune
system of the body to recognise and retaliate against foreign agents rather than
attacking the tumour itself.
The growth of the global immune checkpoint inhibitors market is attributed to the
deteriorating health conditions as well as the rise in exposure to cancerous agents
and pollutants in the environment. With the growing geriatric population, cancer as a
disease is continually spreading and due to low immunity, it is prevalent in the older
Medical science- a dynamic field, cancer cures are discovered regularly and this is
projected to drive the growth of the market. With the advancement in technology,
the cures are becoming more efficient with minimal pain involved thus further
promoting the global market of immune checkpoint inhibitors.
Along with cancer prevalence, immune checkpoint inhibitors also have received
several approvals by the FDA and thus are growing popular as a medical treatment.
However, the discovery, treatment and research are expensive and that is expected
to retrain the growth of the market in the future. Another aspect limiting the
market’s growth is the high incurability rate observed in last stage cancer cases. On
the contrary, growing awareness and knowledge helps the public gain an early
diagnosis and thus helps the market to foster.
Various firms in the field of cancer cure treatments have discovered better efficient
cures thus helping the market to soar. For instance, Bristol-Myers Squibb, an
American pharmaceutical company, developed a powerful combination of Yervoy, a
monoclonal antibody used to treat late-stage, metastatic melanoma, deadly skin
cancer and Opdivo, used in the treatment of patients with metastatic non-small cell
lung cancer. This combination helped in the cases of patients with metastatic
castration-resistant prostate cancer. With several more such discoveries and
combinations in the pipeline, the market is poised to soar and gain huge revenue and
The paradigm shift from conventional mono-therapies to combination Immunooncology therapies has benefitted the market. The global market is competitive yet
consolidated due to the strong presence of established players such as Tecentriq
who have strategically maintained a consistent position in the market through
constant innovation. Keytruda, Imfinzi and Opdivo therapies have received approvals
for application for various ailments. To further elucidate, market drivers are
constantly undertaking research to form immune checkpoint inhibitors and their
combination therapies so as to find more cures. Market influencers are investing in
research to further expand the market and explore its potential. The advent of
innovative immune checkpoint therapies and inhibitors has supported the growth of
the market. For instance, Sanofi, in 2015, entered into a new global collaboration,
with Regeneron Pharmaceuticals, to discover, develop and commercialize new
antibody. This was done to discover the treatment of phase 2 cutaneous squamous
cell carcinoma. Such initiatives are further expected to accelerate the market’s
Request a Sample Report @
Global Immune Checkpoint Inhibitors Market Segmentation
By Drug Class
> PD-1
> PD-L1
> CTLA-4
The PD-1 inhibitor segment garners the maximum revenue and is anticipated to
remain dominant during the forecast period due to the increase in adoption.
However, the demand for PD-L1 inhibitor is also projected to exhibit to grow at the
highest CAGR.
By Therapeutic Application
> Lung Cancer
> Melanoma
> Urothelial Carcinoma
> Squamous Cell Carcinoma
> Blood Cancer
> Other Cancers
The lung cancer segment presently dominates the market and is expected to remain
dominant during the forecast period, due to the rise in the prevalence of lung cancer
given pollution, rise in smokers and allergies across the globe.
By Distribution Channel
> Hospital Pharmacies
> Retail Pharmacies
By Region:
> Europe
> North America
> Latin America
> Rest of World
Asia-Pacific presents lucrative trade opportunities for the immune checkpoint
inhibitors market, owing to the large population base, the surge in the incidence of
cancer, growth in awareness about advanced immune therapy, and improvement of
healthcare infrastructure.
Purchase a Copy of this Premium Research Report & Ask For Discount:
Competitive Landscape
> Tier 1 players- established companies in the market with a major market share
> Tier 2 players
> Emerging players which are growing rapidly
> New Entrants
The major market influencers are AstraZeneca PLC., Bristol-Myers Squibb
Company, Eli Lilly and Company (ARMO Biosciences.), Fortress Biotech, Inc.
(Checkpoint Therapeutics, Inc.), F. Hoffmann-La Roche Ltd. (Genentech, Inc.),
Immutep Limited, Merck & Co., Inc., Merck KGaA (EMD Serono, Inc.), Novartis AG,
and Pfizer Inc.
These firms are mainly concentrating on incorporating value addition programs for
regulating the customer base through the enhancement of product offerings to suit a
diverse range of indications.
FutureWise Takeaways
> Growth prospects
> SWOT analysis
> Key trends
> Key data points affecting market growth
Objectives of the Study
> To provide an exhaustive analysis on the global immune checkpoint inhibitors
market by drug class, by therapeutic application, by distribution channel, by end-user
and by region
> To cater comprehensive information on factors impacting market growth (drivers,
restraints, opportunities, and industry-specific restraints)
> To evaluate and forecast micro-markets and the overall market
> To predict the market size, in key regions (along with countries)—North America,
Europe, Asia Pacific, Latin America, and the Middle East.
> To record evaluate and competitive landscape mapping- product launches,
technological advancements, mergers and expansions
> Profiling of companies to evaluate their market shares, strategies, financials and
core competencies
Table of Contents
 Market Definition
 Market Taxonomy
 Key findings of the study
 CXO perspective
 Futurewise Analysis of the Market
Market Dynamics
factors, Opportunities with Market Size and Forecast 2019 to 2029)
CTLA-4 inhibitor
PD-1 inhibitor
PD-L1 inhibitor
Forecast 2019 to 2029)
 Overview
Lung cancer
Bladder cancer
Hodgkin lymphoma
factors, Opportunities with Market Size and Forecast by Country 2019 to 2029)
North America
> U.S.
> Canada
> Mexico
> Germany
> France
> UK
> Rest of Europe
> Japan
> China
> Australia
> India
> Rest of Asia-Pacific
> Brazil
> Rest of LAMEA
7. COMPANY PROFILES (Company overview, Company snapshot, Operating
business segments, Business performance, Key strategic moves and developments)
> AstraZeneca Plc.
> Bristol-Myers Squibb Company
> Eli Lilly and Company (ARMO BioSciences)
> Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)
> F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
> Immutep Limited
> Merck & Co., Inc.
> Merck KGaA (EMD Serono, Inc.)
> Novartis AG
> Pfizer Inc.
Inquire further details about this report at: [email protected]
About FutureWise Research:
We specialise in high-growth niche markets, assuring flexibility, agility and
customised solutions for our clients. Through in-depth market insights and
consultancy, we present our clients with the tools they need to be at the forefront of
their industry – a position secured for far more than the near future.
Contact Us:
Company Name: FutureWise Research
Contact Person: Vinay Thaploo
Email: [email protected]
Phone: +44 141 628 9353 / +1 970 279 4295
City: Leeds
Country: United Kingdom

Immune checkpoint inhibitors market to value over USD 26 Billion by 2029 end and register a CAGR of over 13.6% from 2019 to 2029.